The Real Role of AI in Market and Customer Insights

Artificial Intelligence has become the center of nearly every conversation happening in pharmaceutical marketing and customer insights functions right now. Depending on the room, AI is either the technology that will finally solve HCP and patient engagement, or the thing that will eliminate the need for insights teams altogether.

Neither view holds up under scrutiny. The reality is that AI is already delivering real value in pharma market and customer insight functions. However, its greatest contribution is not replacing the judgment of insights professionals. It is amplifying it.

Marketing organizations that treat AI as a shortcut to automated decision-making are consistently disappointed. The ones treating it as a tool for accelerating analysis, uncovering patterns, and supporting better decision-making are seeing far more meaningful results.

The Insight Challenge Has Never Been Data

Most pharma marketing organizations are not suffering from a lack of information.

HCP feedback lives in CRM systems, call notes, congress transcripts, medical inquiry logs, patient support programs, market research studies, digital engagement platforms, syndicated data, and social listening tools. Patient experience data adds another layer entirely. The challenge has never been collecting this information.

The challenge is understanding it fast enough to matter. Even experienced insights teams struggle to process the sheer volume now available. Valuable signals about prescriber sentiment, message resonance, or emerging patient needs often remain hidden because teams lack the time to review thousands of verbatims, identify recurring themes, or connect insights across sources.

This is where AI begins to demonstrate genuine value. It can rapidly process large volumes of structured and unstructured information, identify patterns, surface anomalies, and highlight relationships that might otherwise remain unnoticed. Importantly, however, finding patterns is not the same as generating insights.

That requires human interpretation.

What AI Does Well

AI excels at tasks that involve speed, scale, and consistency.

For example, pharma marketing and insights teams can use AI to:

• Analyze thousands of HCP or patient verbatims simultaneously

• Identify emerging sentiment shifts around a brand, therapy area, or competitor

• Group similar feedback into common themes across markets and channels

• Detect early signals in patient support or adherence data

• Summarize lengthy market research reports or advisory board transcripts

• Monitor competitor messaging and launch activity at scale

• Track KOL commentary across congresses and publications

• Generate initial hypotheses for the insights team to investigate further

These activities dramatically reduce the manual effort required to transform raw feedback into something usable. Instead of spending days coding open-ended verbatims or summarizing lengthy research decks, insights teams can spend their time examining what the findings actually mean for the brand.

In this sense, AI improves productivity while expanding analytical capacity. The result is not fewer insights professionals. It is more effective ones.

What AI Does Poorly

The excitement surrounding AI sometimes obscures its limitations, and those limitations carry more weight in pharma than in almost any other industry.

• AI can identify correlations without understanding causation.

• It can summarize what physicians or patients said without appreciating the regulatory or competitive context behind why they said it.

• It can identify a sentiment shift without understanding what that shift means for a brand operating under label constraints, MLR review, or formulary dynamics.

Most importantly, it cannot replace commercial and medical judgment. Consider a situation where HCP engagement with a brand's digital content suddenly declines. An AI system may accurately identify the decline and highlight which content or channels are underperforming. It may even suggest possible explanations. What it cannot do is weigh those findings against a pending label update, an upcoming formulary decision, a competitor's launch timeline, regulatory constraints, or long-term brand strategy. Those decisions remain the responsibility of marketing, medical affairs, and commercial leadership.

AI informs those decisions. It does not own them.

The Difference Between Information and Insight

One of the most common misconceptions in pharma's AI conversation is the belief that more information automatically creates better insight. It does not. Most brand teams already have more dashboards, syndicated reports, and market research decks than they can effectively use. True insight occurs when information is connected to context. For example:

• A decline in HCP message recall is information.

• Understanding which channel or content is driving that decline is analysis.

• Deciding how to adjust the omnichannel strategy, and defending that decision through MLR, is judgment.

AI can contribute significantly to the first two stages. The third stage remains fundamentally human. This is why the most effective pharma marketing organizations position AI as a partner in the insight process rather than a replacement for it. The technology accelerates understanding, but people remain responsible for interpretation and action.

The Future Insights Professional Looks Different

Some market research, customer insights, and brand analytics professionals worry that AI will eliminate their roles. A more likely outcome is transformation rather than replacement. Routine analytical work will continue to become more automated. Verbatim coding, competitive tracking, and first-pass report summarization are increasingly handled by intelligent systems.

At the same time, the value of critical thinking, commercial acumen, and cross-functional judgment will increase. As AI handles more of the mechanical work, insights professionals will spend more time:

• Framing the right brand and commercial questions

• Evaluating competing explanations for what the data shows

• Validating findings against medical, regulatory, and access realities

• Building narratives that move brand and commercial leadership to act

• Connecting customer signals to broader commercial strategy

• Guiding organizational decisions

In other words, the most valuable insights professionals will become less focused on data preparation and more focused on judgment.  

Why Governance Still Matters

There is another reality often overlooked in discussions about AI-powered insights:

The quality of outputs depends on the quality of inputs.

Pharma organizations with fragmented CRM data, inconsistent field definitions across brands or regions, and unclear data lineage frequently struggle to generate reliable AI-driven insights, regardless of how sophisticated the model is.

If HCP records are duplicated across systems, patient program data is not reconciled with commercial data, or the definition of an “engaged HCP” varies by brand team, AI will simply process flawed information faster.

This is why mature organizations invest not only in AI tools but also in the architectural foundations that support them. Data quality, governance, common business definitions, and trusted information sources remain critical prerequisites for effective insight generation. The organizations achieving the most success with AI are often the ones that spent years improving their data foundations before applying advanced analytics.  

Technology amplifies existing strengths and weaknesses. It does not eliminate them.

The Leadership Opportunity

For marketing and insights leaders, the question is not whether AI can generate market and customer insights in pharma. It already can. The more important question is how AI and human expertise can work together inside a highly regulated environment.

Organizations should focus on creating environments where AI accelerates discovery while people provide interpretation, context, and accountability. The leaders who extract the greatest value from AI will not be those seeking to automate judgment. They will be those seeking to augment it. They will use AI to uncover signals faster, identify opportunities sooner, and evaluate information more comprehensively than ever before. But they will continue to rely on experienced insights and commercial professionals to determine what those findings mean and how the brand should respond.

That balance is where real competitive advantage emerges.

The Bottom Line

AI is exceptionally good at processing information, identifying patterns, and accelerating analysis. Insights professionals remain uniquely capable of applying context, regulatory judgment, commercial strategy, and relationships that no model can replicate.

The organizations that thrive will be those that combine both strengths. Because the ultimate goal of customer and market intelligence is not to generate more data. It is to make better brand and commercial decisions, faster.

For more information, please contact us at info@proximo.com or reach out to us at https://www.proximo.com/contact.

‍